

Centre For AIDS Reagents

Data Sheet

| | |
|---------------------------------|---|
| REAGENT: | J-Lat Tat-GFP Cells (A1) |
| RELEASE RESTRICTIONS: | NIH Category C |
| REPOSITORY REFERENCE: | 100 944 |
| PROVIDED: | 1 ml (5.30×10^6 cells/vial), viability is 69%. |
| STORAGE: | Liquid nitrogen. |
| DESCRIPTION: | These cells are Jurkat cells that bear the integrated retroviral construct LTR-Tat-IRES-GFP. |
| LOT NUMBER: | 140084 |
| SPECIAL CHARACTERISTICS: | Jurkat cells were infected with viral particles bearing the retroviral construct LTR-Tat-IRES-GFP. Cells that were GFP negative, but could be stimulated to express GFP were selected. For the other similar cells, please see cat#s 100941-100948. |
| CELL TYPE: | Jurkat - T lymphocyte cell line |
| FREEZE MEDIUM: | FBS, 90%; DMSO, 10%. |
| GROWTH CHARACTERISTIC: | No special requirements, split 1:3 at 1×10^6 cells/ml. Cells grow in suspension, usually singly but some clumping has been noted. |
| PROPAGATION MEDIUM: | RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM, 0.3 mg/ml). |
| MORPHOLOGY: | Small, spherical cells in suspension. Morphology usually does not vary |
| CONTRIBUTOR: | Dr. Eric Verdin. |

REFERENCES:

Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. *EMBO J* **22**:1868-1877, 2003.

Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. *EMBO J* **20**:1726-1738, 2001

ACKNOWLEDGMENT:

The following reagent was obtained by CFAR – NIBSC via the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Tat-GFP Cells (clone #) from Dr. Eric Verdin. Also include the references cited above in any publication.

Please ensure that you send us a copy of any Papers resulting from work using reagents acquired through CFAR, this can be by e-mail or printed copy.